This study focuses on treating recurrent or metastatic head and neck squamous cell carcinoma, a type of cancer that has either come back after initial treatment or spread to other parts of the body. The research evaluates a combination treatment using two medications: ficerafusp alfa (also known as BCA101) and pembrolizumab (KEYTRUDA). These medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.
The purpose of the study is to determine if adding ficerafusp alfa to pembrolizumab works better than pembrolizumab with placebo for patients who have not received previous treatment for their advanced cancer. The study will test two different doses of ficerafusp alfa (750 mg and 1500 mg) to find the most effective and safest dose when combined with pembrolizumab.
During the treatment, participants will receive regular doses of the study medications for up to 24 months. The study will track how well the treatment works by measuring if the cancer shrinks or disappears (tumor response), how long patients live (overall survival), and how long patients live without their cancer getting worse (progression-free survival). The study will also monitor any side effects that participants may experience during treatment.
1Initial treatment assignment
After joining the study, you will be randomly assigned to one of three treatment groups:
– Group A: ficerafusp alfa 1500 mg with pembrolizumab
– Group B: ficerafusp alfa 750 mg with pembrolizumab
– Group C: placebo with pembrolizumab
2Treatment administration
You will receive medication through intravenous infusion (directly into your vein)
The treatment will be given once weekly
Both medications (ficerafusp alfa and pembrolizumab) will be administered as a solution for infusion
3Medical monitoring
Your health will be regularly monitored through:
– Blood tests to check organ function
– Imaging scans to measure tumor response
– Assessment of any side effects
Your doctor will track if the cancer is responding to treatment using standardized measurement criteria (RECIST 1.1)
4Quality of life assessment
You will complete questionnaires about:
– Your overall health status
– Quality of life
– Pain levels related to head and neck cancer
5Study duration
The study is expected to run from November 2025 to July 2029
Your participation length will depend on how your cancer responds to treatment
Treatment will continue until either your disease progresses or you experience unacceptable side effects
Who Can Join the Study?
Must be at least 18 years old when signing the consent form
Must have confirmed cancer that has spread or come back in specific areas of the head and neck (oral cavity, hypopharynx, larynx, or oropharynx)
Must have adequate organ function, including:
– Sufficient blood cell counts
– Good kidney function
– Proper liver function
– Normal blood clotting
Must not have received any previous treatment for cancer that has spread, or must have completed previous treatment at least 6 months ago
Must be willing to provide a tumor tissue sample or undergo a biopsy if needed
Must have a performance status of 0 or 1 (able to perform daily activities with minimal assistance)
Must sign an informed consent form and agree to follow study procedures
For women who can become pregnant:
– Must have a negative pregnancy test
– Must use effective birth control during the study
For men:
– Must agree to use condoms during the study
– Must not donate sperm during the study
Must have specific tumor characteristics that make them eligible for the study medication (pembrolizumab)
Must have measurable disease that can be evaluated by scans
Who Cannot Join the Study?
Prior treatment with any PD-1/PD-L1 inhibitor (a type of immunotherapy drug)
Active brain metastases (cancer that has spread to the brain) or spinal cord compression
History of autoimmune disease requiring systemic treatment in the past 2 years
Active or history of pneumonitis (inflammation of lung tissue)
Uncontrolled heart disease or high blood pressure
Active infection requiring systemic therapy
Known HIV, active hepatitis B, or active hepatitis C infection
History of other cancer within 3 years, except for successfully treated non-melanoma skin cancer or cervical cancer in situ
Pregnancy or breastfeeding
Current participation in other clinical trials
Major surgery within 4 weeks before starting the study treatment
Any condition that could interfere with study procedures or interpretation of results
Known allergies or sensitivity to study medications or their components
Ficerafusp alfa is a new investigational medication being studied for treating head and neck cancer. It is designed to work together with another medication to help fight cancer cells. It is administered once weekly through an intravenous infusion.
Pembrolizumab is an immunotherapy medication that helps the body’s immune system detect and fight cancer cells. It works by blocking a protein called PD-L1 that cancer cells use to hide from the immune system. It is given through an intravenous infusion.
Head and Neck Squamous Cell Carcinoma – A type of cancer that begins in the squamous cells lining the moist surfaces inside the head and neck regions. It typically starts in the mouth, throat, or voice box and can spread to nearby tissues. The cancer forms when squamous cells develop genetic changes, causing them to grow uncontrollably and form tumors. When described as recurrent, it means the cancer has returned after treatment, while metastatic indicates the cancer has spread to other parts of the body beyond its original location.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Ireland 
Italy 
Poland 
Portugal 
Spain 
